文献速递腹部CT

新型氧化钽对比剂在双能CT肝脏成像与肿瘤检测中的评估:一项临床前概念验证研究

Evaluation of a Novel Tantalum Oxide-Based Contrast Agent for Liver Imaging and Tumor Detection in Dual-Energy CT: A Preclinical Proof-of-Concept Study.
PubMed 文献 · Acad Radiol · 2025-07-22

研究在携带0.6-0.9 cm孤立VX2肝肿瘤的兔模型上,比较实验性氧化钽纳米颗粒对比剂TaCZ与碘帕醇在双能CT多期扫描中的肝脏成像和肿瘤检测效果。结果显示TaCZ在50 keV虚拟单能图及各时间点均提供高于碘帕醇的肿瘤对比噪声比、可见度评分和检出率,差异在105 s和180 s延迟期最明显。

要点

  • TaCZ在各时间点的肿瘤对比噪声比、可见度评分和检出率均高于碘帕醇(p<0.001)。
  • 碘帕醇120 kVp的对比增强及肝脏、血管、肿瘤可见度低于50 keV或TaCZ重建(p<0.001)。
  • 两组差异在105 s和180 s延迟期最明显,TaCZ在不同能量水平表现一致。

核心结论

  • 在双能CT上,TaCZ对小型肝肿瘤的检测表现优于碘帕醇,在延迟期和光谱成像中诊断获益更大。

研究设计与样本

  • 临床前概念验证研究,兔VX2肝肿瘤模型(肿瘤0.6-0.9 cm),在人体腹部尺寸容器内用临床双能CT扫描,共10组研究数据集,对比剂元素剂量均为540 mg/kg体重,多期扫描于注射前及注射后6、40、105、180 s进行,重建常规120 kVp和50 keV虚拟单能图。

关键影像表现/征象

  • 碘帕醇120 kVp重建的对比增强及肝脏、血管和肿瘤可见度低于50 keV或TaCZ重建(所有时间点,p<0.001)。
  • TaCZ在各时间点的肿瘤对比噪声比、可见度评分和检出率均高于碘帕醇(p<0.001)。
  • 两组差异在105 s和180 s最明显。
  • TaCZ在不同能量水平表现一致,碘帕醇则不然。

诊断标准与关键数值

  • 由三名放射科医师独立评分肿瘤可见度和检出情况,采用评分制,具体评分标准原文未报告。
  • 对比剂元素剂量为540 mg/kg体重(钽或碘)。

临床应用与阅片要点

  • 在双能CT延迟期和光谱成像(如50 keV虚拟单能图)中,TaCZ对小型肝肿瘤的显示和检出优于碘帕醇。
  • 碘帕醇在常规120 kVp下肝脏、血管和肿瘤可见度较低,评估小肿瘤时需注意。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To evaluate an experimental intravascular carboxybetaine zwitterionic tantalum oxide (TaCZ) nanoparticle CT contrast agent versus iopamidol for hepatic imaging and tumor detection using a multiphase dual-layer spectral CT (DLCT).

MATERIALS AND METHODS: Rabbits with small (0.6 - 0.9 cm) solitary VX2 hepatic tumors were scanned on a clinical DLCT within a human abdomen-sized encasement resulting in a total of 10 study sets. Multiphase scans were acquired before and at 6, 40, 105, and 180 s post-injection of 540 mg of contrast element (Ta or I) per kg of body weight, using either TaCZ or iopamidol. Conventional 120 kVp and 50 keV virtual monoenergetic images were reconstructed to assess liver, portal vein, and hepatic tumor enhancement. Three radiologists independently rated conspicuity and tumor detection.

RESULTS: Iopamidol at 120 kVp showed significantly lower contrast enhancement and poorer liver, vessel and tumor conspicuity compared to 50 keV or TaCZ reconstructions (all time points; p < 0.001). TaCZ provided higher tumor contrast-to-noise ratios, conspicuity scores, and detection rates than iopamidol across all time points (p < 0.001). Differences were most pronounced at 105 and 180 s. TaCZ demonstrated consistent performance across energy levels, unlike iopamidol.

CONCLUSION: TaCZ outperformed iopamidol for small liver tumor detection on DLCT, with greater diagnostic benefit at delayed phases and spectral imaging.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Heimer MM, Sun Y, Aschauer T, et al. Evaluation of a Novel Tantalum Oxide-Based Contrast Agent for Liver Imaging and Tumor Detection in Dual-Energy CT: A Preclinical Proof-of-Concept Study. Acad Radiol. 2025. PMID: 40701858. doi:10.1016/j.acra.2025.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。